Tesamorelin
FDA ApprovedTesamorelin
- Category
- Growth Hormone
- Aliases
- Egrifta, Egrifta SV
- Administration
- Subcutaneous injection (once daily)
Documented side effects
Tier 1 · Peer-reviewed / regulatoryInjection site reactions
Mild redness, swelling, or discomfort at the site of injection.
Joint pain
Some users report discomfort in the joints during use.
Peripheral edema
Mild swelling, typically in the lower legs or feet, has been reported with use.
Potential blood sugar elevation
May raise blood glucose levels as a downstream effect of increased growth hormone activity.